Akeso Inc. has announced that its first bispecific Antibody-Drug Conjugate $(ADC)$, AK146D1, has received regulatory approval to commence clinical trials from the U.S. Food and Drug Administration (FDA), Australia's Therapeutic Goods Administration $(TGA)$, and China's National Medical Products Administration (NMPA). This marks a significant milestone for Akeso, as AK146D1 targets both Trop2 and Nectin4, representing a key component of the company's "IO+ADC" 2.0 strategy aimed at advancing cancer therapies. The approval allows Akeso to proceed with its Phase Ia clinical trial, with the first patient already successfully enrolled.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.